Algazi, Alain

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 2,810

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,069

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 966

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics

Hippo pathway signaling and YAP/TAZMelanoma and MAPK Pathways

Cited by 551

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 525

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

Rahim, M. K., Okholm, T. L. H., Jones, K. B., McCarthy, E. E., Liu, C. C., Yee, J. L., Tamaki, S. J., Marquez, D. M., Tenvooren, I., Wai, K., et al. (2023) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 455

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 449

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 338

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

Algazi, A. P., Rotow, J., Posch, C., Ortiz‐Urda, S., Pelayo, A., Munster, P. N., & Daud, A. (2019) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 23